Publications
Detailed Information
Preoperative serum HER2 extracellular domain levels in primary invasive breast cancer
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Lee, Sae Byul | - |
dc.contributor.author | Lee, Jong Won | - |
dc.contributor.author | Yu, Jong Han | - |
dc.contributor.author | Ko, Beom Seok | - |
dc.contributor.author | Kim, Hee Jeong | - |
dc.contributor.author | Son, Byung Ho | - |
dc.contributor.author | Gong, Gyungyub | - |
dc.contributor.author | Lee, Hee Jin | - |
dc.contributor.author | Kim, Sung-Bae | - |
dc.contributor.author | Jung, Kyung Hae | - |
dc.contributor.author | Ahn, Jin-Hee | - |
dc.contributor.author | Lee, Woochang | - |
dc.contributor.author | Sung, Joohon | - |
dc.contributor.author | Ahn, Sei-Hyun | - |
dc.date.accessioned | 2017-02-08T00:32:21Z | - |
dc.date.available | 2017-02-08T00:32:21Z | - |
dc.date.issued | 2014-12-10 | - |
dc.identifier.citation | BMC Cancer, 14(1):929 | ko_KR |
dc.identifier.uri | https://hdl.handle.net/10371/100512 | - |
dc.description | This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. | ko_KR |
dc.description.abstract | Abstract
Background Despite the preclinical outcomes and biologic significance of the presence of the human epidermal growth factor receptor-2 (HER2) extracellular domain (ECD), there is little evidence supporting the measurement of ECD levels in any clinical setting. The aim of this study was to determine the prevalence of elevated serum HER2 ECD levels, the association between these levels and tissue HER2 overexpression, and the potential clinical prognostic value of HER2 ECD in primary invasive breast cancer. Methods Serum HER2 ECD levels were examined preoperatively in 2,862 consecutive stage I–III primary breast cancer patients between 2007 and 2009. Serum HER2 ECD levels were measured by chemiluminescence immunoassay (ADVIA Centaur), and the tissue HER2 status was assessed by immunohistochemistry and fluorescence in situ hybridization. The cutoff value for the serum level of HER2 ECD was set at 15.2ng/ml. Results Among the 2,862 patients, 126 (4.4%) had elevated serum HER2 ECD levels, and HER2 was overexpressed in the tumor tissue of 692 patients (24.2%), with a concordance of 78.7%. Multivariate analysis revealed that elevated serum HER2 ECD was a significant independent prognostic factor for worse distant-metastasis-free survival [DMFS; hazard ratio (HR) = 2.50, 95% confidence interval (CI) = 1.5–4.3, P = 0.001] and breast-cancer-specific survival (BCSS; HR = 2.0, 95% CI = 1.1–3.8, P = 0.036), which were much stronger in patients with tissue HER2-positive tumors (DMFS: HR = 3.8, 95% CI = 2.0–7.0, P < 0.001; BCSS: HR = 2.6, 95% CI = 1.2-5.3, P = 0.012). Conclusions Given the prevalence of HER2 expression, its measurement as an independent prognostic factor can be clinically useful, particularly in patients with tissue HER2-positive tumors. | ko_KR |
dc.language.iso | en | ko_KR |
dc.publisher | BioMed Central | ko_KR |
dc.subject | HER2 extracellular domain | ko_KR |
dc.subject | HER2 breast cancer | ko_KR |
dc.subject | Prognostic factor | ko_KR |
dc.title | Preoperative serum HER2 extracellular domain levels in primary invasive breast cancer | ko_KR |
dc.type | Article | ko_KR |
dc.contributor.AlternativeAuthor | 이새별 | - |
dc.contributor.AlternativeAuthor | 이종원 | - |
dc.contributor.AlternativeAuthor | 유종한 | - |
dc.contributor.AlternativeAuthor | 고범석 | - |
dc.contributor.AlternativeAuthor | 김희정 | - |
dc.contributor.AlternativeAuthor | 손병호 | - |
dc.contributor.AlternativeAuthor | 공경엽 | - |
dc.contributor.AlternativeAuthor | 이희진 | - |
dc.contributor.AlternativeAuthor | 김성배 | - |
dc.contributor.AlternativeAuthor | 정경해 | - |
dc.contributor.AlternativeAuthor | 안진희 | - |
dc.contributor.AlternativeAuthor | 이우창 | - |
dc.contributor.AlternativeAuthor | 성주헌 | - |
dc.contributor.AlternativeAuthor | 안세현 | - |
dc.identifier.doi | 10.1186/1471-2407-14-929 | - |
dc.language.rfc3066 | en | - |
dc.rights.holder | Lee et al.; licensee BioMed Central Ltd. | - |
dc.date.updated | 2017-01-06T10:10:37Z | - |
- Appears in Collections:
- Files in This Item:
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.